As published on Yahoo Finance, Code Pharma announced encouraging results from an eight-week study of Gammora, a drug targeting human immunodeficiency virus (HIV), revealing potential for a cellular-level cure. These preliminary findings were presented at the 2024 HIV Drug Therapy Conference in Glasgow, Scotland.
Gammora, a peptide derived from HIV-1 integrase, works by promoting the insertion of the virus’s genetic material into the DNA of infected cells. In an open-label, randomized clinical trial, Gammora combined with protease inhibitor (PI)-based antiretroviral therapy (ART) demonstrated a safe reduction in the HIV reservoir—the pool of HIV-infected cells—without damaging nearby healthy cells, a risk often associated with ART alone.
“These incredibly positive outcomes offer new hope at a time when 40 million individuals worldwide are impacted by HIV and the current standard of care with ART drugs does not offer a cure at the cellular level,” said Eynat Finkelshtein, PhD., Chief Scientific Officer of Code Pharma.